Skip to main content
. 2023 Jun 19;67(6):e000654. doi: 10.20945/2359-3997000000654

Table 3. Endocrine-related adverse events according to ICI type.

Primary thyroid dysfunction, n (%) 14 (100)
Anti-PD-1a 11 (78.6)
Anti-PDL-1b 3 (21.4)
Hypopituitarism, n (%) 8 (100)
Anti-PD-1a 8 (100)

Abbreviations: ICI, immune checkpoint inhibitor; PD, programmed death; PD-L, programmed death ligand.

a

Anti-PD-1 treatment: nivolumab or pembrolizumab

b

Anti-PDL-1 treatment: atezolizumab or durvalumab